Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2012

Eliquis(Apixaban)Bristol-Myers Squibb Company logoBMY

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Bristol-Myers Squibb Company

$20.77B

Medicare cost, 2024

Medicare drug plans spent $20.8 billion on Eliquis (apixaban) in 2024, for 24.1 million prescriptions and refills filled by 4.4 million patients. It is the drug Medicare drug plans spend the most on. Florida accounts for the most spending ($1.6 billion, 8% of the total). It is made by Bristol-Myers Squibb Company (BMY).

Medicare cost, 2024

$20.77B

+13.7% from 2023

Prescriptions

24.1M

$863.42 per claim

Patients

4.4M

556,431 prescribers

Total spending, 2024

$20.77B

$4,695.12 per patient

Questions and answers

How much does Medicare spend on Eliquis?

Medicare prescription drug plans paid $20.77B for Eliquis in 2024, for 24,054,695 prescriptions and refills to 4,423,497 patients (up 13.7% from 2023). The average cost per claim was $863.42.

Which state spends the most on Eliquis?

Florida had the highest Medicare cost for Eliquis in 2024: $1.58B for 1,734,859 claims, followed by California ($1.58B).

Who prescribes Eliquis the most?

Jennifer L Tresser, pharmacist in Martinez, CA, had the highest Medicare cost for Eliquis in 2024: 5,156 claims costing $8.7M.

Who makes Eliquis?

Eliquis is made by Bristol-Myers Squibb Company (BMY), listed in the Medicare spending data as BMS Primarycare.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Eliquis was $20.77B in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Eliquis, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Jennifer L Tresser Martinez, CAPharmacist5,1561,953$8.7M
Huong K Ha Sepulveda, CAPharmacist2,9831,087$4.5M
Elena M Wellen Wilmington, NCPharmacist2,6981,075$4.4M
Cindy S Kennedy Charlotte, NCPharmacist2,569851$4.0M
Carmen Wong Union City, CAPharmacist2,620950$3.9M
Wassim Shaheen Wichita, KSInterventional Cardiology3,943765$3.7M
Jeanne C Benoit Quincy, MANurse Practitioner3,125828$3.7M
Hyeon Hye Lee Cupertino, CAPharmacist2,298882$3.7M
Samantha J Seivert Wilmington, NCPharmacist2,2171,005$3.5M
Mohamed H Khan Redding, CAInterventional Cardiology2,431716$3.5M
Robert J Pearlstein Plymouth Meeting, PAInternal Medicine13,4681,101$3.5M
Jordan Wong San Francisco, CAPharmacist2,178774$3.3M
Glenn H Herrington Wilmington, NCPharmacist1,900914$3.1M
Maria R Peluso Winston Salem, NCPharmacist1,914671$3.1M
Gad A Silberman Tallahassee, FLClinical Cardiac Electrophysiology3,713564$2.7M
Michael P Boyle Ocean View, DENurse Practitioner2,054754$2.7M
Mischell E Schlosser Toledo, OHNurse Practitioner2,387920$2.6M
Timir S Baman Peoria, ILClinical Cardiac Electrophysiology2,010517$2.5M
Mayer Rashtian Pasadena, CAClinical Cardiac Electrophysiology2,105544$2.4M
Zoheir A Abdelbaki Lima, OHCardiology1,962532$2.4M
Hazar Dahhan Manchester, CTCardiology1,730424$2.4M
Lance E Sullenberger Albany, NYCardiology1,578482$2.3M
Jeannie Poon Mooresville, NCPharmacist1,473490$2.3M
Majed Nounou Lapeer, MIInterventional Cardiology1,857525$2.3M
Samantha J Bialecki Toledo, OHNurse Practitioner2,033806$2.3M

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022496,98918,969,1143,504,386$15.22B
2023526,72521,185,7513,925,487$18.27B
2024556,43124,054,6954,423,497$20.77B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
BMS PrimarycareBMY logoBMY24,061,332$20.77B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
28
RxNorm concept IDs
1364435, 1364441, 1364445, 1364447
Application numbers
NDA202155

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube